12.05.19
A randomized double-blind, placebo-controlled clinical trial published in the Journal of Arthritis evaluated the efficacy of Stratum Nutrition’s flagship ingredient, NEM brand eggshell membrane, in 166 subjects diagnosed with Grade 2 or Grade 3 osteoarthritis of the knee.
This study was conducted at eight different university medical centers in Turkey and confirmed NEM offered benefits in 7 days. By day 30, both knee pain and stiffness had improved by more than 30% in the NEM-treated subjects. This study also employed a unique blinded, single-crossover design to compare subjects taking NEM for 90 days versus subjects taking NEM for 60 days (the former placebo subjects who began taking NEM after day 30).
A responder analysis found a statistically significant difference between the number of patients having at least a 15% decrease in pain, which was greater in the 90-day NEM group (71% of subjects) compared to the 60-day NEM group (53% of subjects).
“This is the largest study conducted to date involving NEM and we are pleased that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis,” said Kevin Ruff, PhD, senior director of scientific and regulatory affairs for Stratum Nutrition. “This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM the perfect adjunctive therapy for those with joint issues.”
This study was conducted at eight different university medical centers in Turkey and confirmed NEM offered benefits in 7 days. By day 30, both knee pain and stiffness had improved by more than 30% in the NEM-treated subjects. This study also employed a unique blinded, single-crossover design to compare subjects taking NEM for 90 days versus subjects taking NEM for 60 days (the former placebo subjects who began taking NEM after day 30).
A responder analysis found a statistically significant difference between the number of patients having at least a 15% decrease in pain, which was greater in the 90-day NEM group (71% of subjects) compared to the 60-day NEM group (53% of subjects).
“This is the largest study conducted to date involving NEM and we are pleased that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis,” said Kevin Ruff, PhD, senior director of scientific and regulatory affairs for Stratum Nutrition. “This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM the perfect adjunctive therapy for those with joint issues.”
